Carbapenem-Resistant Enterobacteriaceae Infection Market Insights and Market Forecast 2030

(MENAFN- GetNews) DelveInsight has added a new research study on Carbapenem-Resistant Enterobacteriaceae Infection market Report with detailed information on the overview, market insights, drugs industry, treatment, growth, size, share, trends, during the forecast period of 2017 to 2030.

Carbapenem-Resistant Enterobacteriaceae Infection Overview

Carbapenems, a class of ß-lactam antibiotics with a broad spectrum of activity, have been the workhorse for treating difficult Gram-negative infections, but with the increasing use of carbapenems in clinical practice, the emergence of Carbapenem-resistant pathogens now poses a great threat to human health.

The Centers for Disease Control and Prevention (CDC) defines Carbapenem-resistant Enterobacteriaceae (CRE) as enterobacteria non-susceptible to any carbapenem or documented to produce carbapenemases. These pathogens have also been described as“nightmare” bacteria by CDC. Also, in 2017, WHO categorized CRE within the critical priority group, against which there is an urgent need to develop new antibiotics.

Request free sample copy @

Regions Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

List of companies involved in the report

• Deerfield Management Company
• Cipla
• Merck
• Pfizer/AbbVie
• Shionogi
• Merck
• La Jolla
• And many others

Carbapenem-Resistant Enterobacteriaceae Infection Symptoms

Symptoms of a CRE infection vary. They may differ with the type of bacteria involved and the part of the body infected. Some general symptoms of a CRE infection include fever and a rapid pulse. Based on carbapenemase production, CRE is classified into carbapenemase-producing CRE and non- carbapenemase-producing CRE.

Carbapenem-Resistant Enterobacteriaceae Infection Mechanisms

There are three major mechanisms by which Enterobacteriaceae become resistant to carbapenems: enzyme production (carbapenemases), efflux pumps, and porin mutations. Of these, enzyme production is the main resistance mechanism. CP-CRE can produce a large variety of carbapenemases, divided into three groups according to the Ambler classification: Class A, Class B, and Class D ß-lactamases. There is a fourth class, Ambler class C; however, its clinical relevance remains unknown.

Carbapenem-resistant Enterobacteriaceae Infection Diagnosis

It covers the details of conventional and current medical therapies and diagnoses available in the Carbapenem-resistant Enterobacteriaceae Infection market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

Carbapenem-resistant Enterobacteriaceae Infection Market Report

The DelveInsight Carbapenem-resistant Enterobacteriaceae Infection market report gives a thorough understanding of Carbapenem-resistant Enterobacteriaceae Infection by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Carbapenem-resistant Enterobacteriaceae Infection in the US, Europe, and Japan.

Carbapenem-resistant Enterobacteriaceae Infection Market Growth

In healthcare settings, CRE are transmitted from person to person, often via the hands of healthcare personnel or through contaminated medical equipment. Additionally, sink drains and toilets are increasingly recognized as environmental reservoirs and CRE transmission sources.

Carbapenem-resistant Enterobacteriaceae Infection Market Insights

The scientific community has focused its efforts on identifying new strategies for combating drug resistance by repositioning non-antibiotic drugs in the antimicrobial arsenal or conceptualizing old antibiotics. One of the methodologies in the post-antibiotic era is the use of non-antibiotic drugs for the treatment of multidrug-resistant infections. The benefits are considerable; the details of these drugs' pharmacokinetics and toxicity are already known, and therefore the drugs can be passed directly into phase 2 of clinical trials. However, the costly disadvantage of clinical trials and patent rights remains.

Carbapenem-resistant Enterobacteriaceae Infection Market Report Scope

• The report covers the descriptive overview of Carbapenem-resistant Enterobacteriaceae Infection, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight has been provided into the Carbapenem-resistant Enterobacteriaceae Infection epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Carbapenem-resistant Enterobacteriaceae Infection is provided, along with the assessment of new therapies which will impact the current treatment landscape.
• A detailed review of the Carbapenem-resistant Enterobacteriaceae Infection market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Carbapenem-resistant Enterobacteriaceae Infection market

Carbapenem-Resistant Enterobacteriaceae Infection Emerging Drugs

• WCK 5222/ FEP-ZID/Zidebactam-Cefepime (Wockhardt)
• ATM-AVI/Aztreonam-avibactam (Pfizer/AbbVie)
• And many others

Request free sample copy @

Table of content

• Key Insights
• Report Introduction
• CRE Infections Market Overview at a Glance
• Executive Summary of Carbapenem-resistant Enterobacteriaceae
• Disease Background and Overview
• Organizations contributing toward the fight against CRE Infections
• Patient Journey
• Case Study
• Epidemiology and Patient Population
• Marketed Products
• Emerging Therapies
• Other Assets in Development
• Carbapenem-resistant Enterobacteriaceae (CRE): Seven Major Market Analysis
• KOL Views
• Market Access
• Unmet Needs
• Market Barriers
• Market Drivers
• SWOT Analysis
• Appendix
• Report Methodology
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Carbapenem-resistant Enterobacteriaceae Market Report Highlights

• In the coming years, the Carbapenem-resistant Enterobacteriaceae Infection market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Carbapenem-resistant Enterobacteriaceae Infection R & D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Carbapenem-resistant Enterobacteriaceae Infection. The launch of emerging therapies will significantly impact the Carbapenem-resistant Enterobacteriaceae Infection market
• A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Carbapenem-resistant Enterobacteriaceae Infection.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 Why should you buy this report?

• The report will help in developing business strategies by understanding trends shaping and driving the Carbapenem-resistant Enterobacteriaceae Infection market
• To understand the future market competition in the Carbapenem-resistant Enterobacteriaceae Infection market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Carbapenem-resistant Enterobacteriaceae Infection in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Carbapenem-resistant Enterobacteriaceae Infection market
• To understand the future market competition in the Carbapenem-resistant Enterobacteriaceae Infection market.

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R & D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:

MENAFN24092021003238003268ID1102860158